Stay updated on Nivolumab for Uterine Cancer - Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Uterine Cancer - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Uterine Cancer - Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:36.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now includes specific inclusion and exclusion criteria for participants with metastatic or recurrent uterine cancer.
    Difference
    40%
    Check dated 2024-05-22T21:29:06.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:44.000Z thumbnail image

Stay in the know with updates to Nivolumab for Uterine Cancer - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Uterine Cancer - Clinical Trial page.